Multicenter Trial of Prednisone in Alzheimer's Disease
- Conditions
- Alzheimer Disease
- Registration Number
- NCT00000178
- Lead Sponsor
- National Institute on Aging (NIA)
- Brief Summary
This is a randomized placebo controlled, double blind study. Patients who meet eligibility criteria and decide to participate in the study will be randomly assigned to receive either drug treatment or a placebo. Neither the patients nor the participating investigators will know who is receiving the drugs and who is receiving the placebo. Participation involves 15 outpatient clinic visits over a 68 week period. Patients take study medication at varying doses (the maximum dose is 20 mg daily), along with calcium and vitamin supplements.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
- Patients with Alzheimer's disease who are in stable medical condition
- Patients with diabetes or severe osteoporosis
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (19)
University of Alabama, Birmingham
๐บ๐ธBirmingham, Alabama, United States
University of Southern California
๐บ๐ธLos Angeles, California, United States
University of California, San Diego
๐บ๐ธSan Diego, California, United States
Mayo Clinic Jacksonville
๐บ๐ธJacksonville, Florida, United States
University of Miami
๐บ๐ธMiami, Florida, United States
University of South Florida
๐บ๐ธTampa, Florida, United States
Indiana University Alzheimer's Center
๐บ๐ธIndianapolis, Indiana, United States
University of Kansas Medical Center
๐บ๐ธKansas City, Kansas, United States
Johns Hopkins University
๐บ๐ธBaltimore, Maryland, United States
University of Minnesota
๐บ๐ธMinneapolis, Minnesota, United States
Scroll for more (9 remaining)University of Alabama, Birmingham๐บ๐ธBirmingham, Alabama, United States